← Leaderboards
Brent K. Hollenbeck
Massachusetts General Hospital
$12,084,917
Attributed
$19,187,677
Total exposure
11
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.3M · FY2010–25$5M$3.8M$2.5M$1.3M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,473,262 · 8
AHRQ$4,714,415 · 3
By mechanism
R01$16,387,402 · 9
T32$2,222,690 · 1
R34$577,585 · 1
Top collaborators
- Vahakn B Shahinian25 shared
- Ganesh S Palapattu8 shared
- Chandy Skaria Ellimoottil3 shared
- Andrew M Ryan2 shared
- Anne Evelyn Sales2 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Jessica Elizabeth Haberer$14,425,308
- William Taylor Kimberly$6,410,197
- Matthew Scot Rosen$2,212,634
- Calum A. Macrae$21,291,852
- Shannon L Stott$3,615,955
Others in their field
Top investigators on “Physicians”
- Lawrence Corey · Fred Hutchinson Cancer Center$289,810,358
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$289,810,358
- Larry Arthur$216,200,000
- Richard K. Wilson · Washington University$201,652,538
- Ralph Parchment · Leidos Biomedical Research, Inc.$141,315,269
- Richard L Schilsky · University Of Chicago$117,759,216
Research focus
PhysiciansMedicareFinancial IncentiveCaringCostIncentivesMalignant Neoplasm Of ProstateUrologistPaymentUrologyInterestProviderHealthcareStructureSavingsHeterogeneityDesignGrowthHospitalsMalignant NeoplasmsFosteringOperative Surgical ProceduresVariantImage
Grant awards (48)
Physician dispensing of oral specialty drugs for advanced prostate cancer and its implications for patients$1,411,059
R01 · FY2025 · CA · contact PI
Aligning financial incentives to promote rational use of active surveillance for prostate cancer$663,204
R01 · FY2025 · CA
Urology practice consolidation and care for men with prostate cancer$585,584
R01 · FY2025 · CA
Effects of integration of advanced practice providers into surgical group practice$391,216
R01 · FY2025 · HS
Planning to implement high-quality active surveillance in new-onset favorable risk prostate cancer$250,089
R34 · FY2025 · CA
Urology practice consolidation and care for men with prostate cancer$593,112
R01 · FY2024 · CA
Aligning financial incentives to promote rational use of active surveillance for prostate cancer$451,145
R01 · FY2024 · CA
Physician dispensing of oral specialty drugs for advanced prostate cancer and its implications for patients$400,622
R01 · FY2024 · CA · contact PI
Effects of integration of advanced practice providers into surgical group practice$396,696
R01 · FY2024 · HS
Planning to implement high-quality active surveillance in new-onset favorable risk prostate cancer$327,496
R34 · FY2024 · CA
Accelerating the Shift to Downside Risk in Medicare Accountable Care Organizations: Effects on Clinical Quality and Costs among Older Patients$213,967
R01 · FY2024 · AG · contact PI
Accelerating the Shift to Downside Risk in Medicare Accountable Care Organizations: Effects on Clinical Quality and Costs among Older Patients$158,794
R01 · FY2024 · AG · contact PI
Physician dispensing of oral specialty drugs for advanced prostate cancer and its implications for patients$94,664
R01 · FY2024 · CA · contact PI
Aligning financial incentives to promote rational use of active surveillance for prostate cancer$559,381
R01 · FY2023 · CA
Physician dispensing of oral specialty drugs for advanced prostate cancer and its implications for patients$530,886
R01 · FY2023 · CA · contact PI
Effects of integration of advanced practice providers into surgical group practice$396,696
R01 · FY2023 · HS · contact PI
Accelerating the Shift to Downside Risk in Medicare Accountable Care Organizations: Effects on Clinical Quality and Costs among Older Patients$325,346
R01 · FY2023 · AG · contact PI
Accelerating the Shift to Downside Risk in Medicare Accountable Care Organizations: Effects on Clinical Quality and Costs among Older Patients$45,741
R01 · FY2023 · AG · contact PI
Physician dispensing of oral specialty drugs for advanced prostate cancer and its implications for patients$44,922
R01 · FY2023 · CA · contact PI
Aligning financial incentives to promote rational use of active surveillance for prostate cancer$578,436
R01 · FY2022 · CA · contact PI
Advanced Training in Urologic Oncology$417,656
T32 · FY2022 · CA
Accelerating the Shift to Downside Risk in Medicare Accountable Care Organizations: Effects on Clinical Quality and Costs among Older Patients$339,949
R01 · FY2022 · AG · contact PI
Advanced Training in Urologic Oncology$387,024
T32 · FY2021 · CA
Impact of urologist practice organization and health policy on prostate cancer treatment, overtreatment and spending$327,954
R01 · FY2021 · HS
Advanced Training in Urologic Oncology$396,027
T32 · FY2020 · CA
Impact of urologist practice organization and health policy on prostate cancer treatment, overtreatment and spending$327,954
R01 · FY2020 · HS · contact PI
Accountable care organizations and the diffusion of new surgical procedures$522,044
R01 · FY2019 · AG · contact PI
Impact of urologist practice organization and health policy on prostate cancer treatment, overtreatment and spending$327,954
R01 · FY2019 · HS · contact PI
Advanced Training in Urologic Oncology$285,032
T32 · FY2019 · CA
Accountable care organizations and the diffusion of new surgical procedures$522,044
R01 · FY2018 · AG · contact PI
Major surgery in patients with Alzheimer's disease and related dementias: effects of technology and policy$373,907
R01 · FY2018 · AG · contact PI
Impact of urologist practice organization and health policy on prostate cancer treatment, overtreatment and spending$320,154
R01 · FY2018 · HS · contact PI
Accountable care organizations and the diffusion of new surgical procedures$530,423
R01 · FY2017 · AG · contact PI
Impact of urologist practice organization and health policy on prostate cancer treatment, overtreatment and spending$396,240
R01 · FY2017 · HS · contact PI
Advanced Training in Urologic Oncology$230,976
T32 · FY2017 · CA
Accountable care organizations and the diffusion of new surgical procedures$530,423
R01 · FY2016 · AG · contact PI
Impact of Urologist Practice Structure on Prostate Cancer Care$362,271
R01 · FY2016 · CA · contact PI
Advanced Training in Urologic Oncology$146,806
T32 · FY2016 · CA
Accountable care organizations and the diffusion of new surgical procedures$570,264
R01 · FY2015 · AG · contact PI
Impact of Urologist Practice Structure on Prostate Cancer Care$362,271
R01 · FY2015 · CA · contact PI
Advanced Training in Urologic Oncology$211,665
T32 · FY2015 · CA
Impact of Urologist Practice Structure on Prostate Cancer Care$422,156
R01 · FY2014 · CA · contact PI
Advanced Training in Urologic Oncology$147,504
T32 · FY2014 · CA
Impact of Urologist Practice Structure on Prostate Cancer Care$480,372
R01 · FY2013 · CA · contact PI
Ambulatory Surgery Centers and Medicare Expenditures for Outpatient Procedures$418,074
R01 · FY2013 · HS · contact PI
Ambulatory Surgery Centers and Medicare Expenditures for Outpatient Procedures$449,657
R01 · FY2012 · HS · contact PI
Ambulatory Surgery Centers and Medicare Expenditures for Outpatient Procedures$463,770
R01 · FY2011 · HS · contact PI
Ambulatory Surgery Centers and Medicare Expenditures for Outpatient Procedures$498,050
R01 · FY2010 · HS · contact PI